| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
DAPT | 208255-80-5 | sc-201315 sc-201315A sc-201315B sc-201315C | 5 mg 25 mg 100 mg 1 g | $40.00 $120.00 $480.00 $2141.00 | 47 | |
DAPT inhibits γ-secretase, an enzyme responsible for the cleavage of Notch receptors. This prevents the release of the Notch intracellular domain (NICD) and subsequent activation of Notch signaling, crucial in cellular differentiation and development. | ||||||
RO-4929097 | 847925-91-1 | sc-364602 sc-364602A | 10 mg 50 mg | $439.00 $1417.00 | 1 | |
RO4929097 is a γ-secretase inhibitor that blocks the proteolytic cleavage of Notch receptors, preventing the release of the active Notch intracellular domain (NICD). This disrupts Notch signaling, affecting cell fate determination and tissue homeostasis. | ||||||
PF-3084014 | 1290543-63-3 | sc-507501 | 5 mg | $130.00 | ||
PF-03084014 is a γ-secretase inhibitor that interferes with Notch signaling by blocking the cleavage of Notch receptors. This inhibits the release of NICD and alters cellular processes like differentiation and proliferation, making it a potential anti-cancer agent. | ||||||
MK-0752 | 471905-41-6 | sc-364534 sc-364534A | 10 mg 50 mg | $592.00 $1550.00 | ||
MK-0752 is a γ-secretase inhibitor that targets Notch signaling by preventing the cleavage of Notch receptors. This inhibits the release of NICD and affects cellular differentiation and proliferation, showing potential in cancer therapy and other diseases. | ||||||
BMS-906024 | 1401066-79-2 | sc-507372 | 10 mg | $3600.00 | ||
BMS-906024 is a selective γ-secretase inhibitor that blocks the cleavage of Notch receptors. This impedes the release of NICD and its downstream signaling, impacting cellular processes like differentiation and growth, offering potential for cancer research. | ||||||
BMS-708163 | 1146699-66-2 | sc-364444 sc-364444A | 10 mg 50 mg | $480.00 $1455.00 | 1 | |
Avagacestat is a γ-secretase inhibitor that prevents the cleavage of Notch receptors. By inhibiting NICD release, it affects Notch signaling, with potential therapeutic implications in diseases involving aberrant cell differentiation and proliferation, such as cancer. | ||||||